A syngeneic mouse model of metastatic renal cell carcinoma for quantitative and longitudinal assessment of preclinical therapies

Katherine A Murphy, Britnie R. James, Andrew Wilber, Thomas S Griffith

Research output: Contribution to journalArticle

7 Scopus citations

Abstract

Renal cell carcinoma (RCC) affects > 60,000 people in the United States annually, and ~ 30% of RCC patients have multiple metastases at the time of diagnosis. Metastatic RCC (mRCC) is incurable, with a median survival time of only 18 months. Immune-based interventions (e.g., interferon (IFN) and interleukin (IL)-2) induce durable responses in a fraction of mRCC patients, and multikinase inhibitors (e.g., sunitinib or sorafenib) or anti-VEGF receptor monoclonal antibodies (mAb) are largely palliative, as complete remissions are rare. Such shortcomings in current therapies for mRCC patients provide the rationale for the development of novel treatment protocols. A key component in the preclinical testing of new therapies for mRCC is a suitable animal model. Beneficial features that recapitulate the human condition include a primary renal tumor, renal tumor metastases, and an intact immune system to investigate any therapy-driven immune effector responses and the formation of tumor-induced immunosuppressive factors. This report describes an orthotopic mRCC mouse model that has all of these features. We describe an intrarenal implantation technique using the mouse renal adenocarcinoma cell line Renca, followed by the assessment of tumor growth in the kidney (primary site) and lungs (metastatic site).

Original languageEnglish (US)
Article numbere55080
JournalJournal of Visualized Experiments
Volume2017
Issue number122
DOIs
StatePublished - Apr 12 2017

Keywords

  • Cancer Research
  • Intrarenal
  • Issue 122
  • Kidney
  • Luciferase
  • Metastasis
  • Orthotopic
  • Renal cell carcinoma

Fingerprint Dive into the research topics of 'A syngeneic mouse model of metastatic renal cell carcinoma for quantitative and longitudinal assessment of preclinical therapies'. Together they form a unique fingerprint.

Cite this